{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:46:56Z","timestamp":1789501616237,"version":"build-2803163510"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Valneva Austria, GmbH"},{"name":"Coalition for Epidemic Preparedness Innovation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chikungunya is a serious and debilitating viral infection with a significant disease burden. VLA1553 (IXCHIQ\u00ae) is a live-attenuated vaccine licensed for active immunization for prevention of disease caused by chikungunya virus (CHIKV).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Immunogenicity following a single dose of VLA1553 was evaluated in healthy adults aged \u226518\u00a0years in two Phase 3 trials [N\u2009=\u2009656 participants (per protocol analysis set)]. Immunogenicity data to 180\u00a0days post-vaccination [geometric mean titres (GMTs), seroresponse rate, seroconversion rate] were pooled for the two trials. A comparison of subgroups based on age, sex, body mass index (BMI), race and baseline seropositivity was included. All analyses were descriptive.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Most participants were aged 18\u201364\u00a0years (N\u2009=\u2009569\/656 [86.7%]), there were slightly more females (N\u2009=\u2009372\/656 [56.7%]), most were not Hispanic\/Latino (N\u2009=\u2009579\/656 [88.3%]), and most were White (N\u2009=\u2009517\/656 [78.8%]). In baseline seronegative participants, GMT peaked at Day 29 post-vaccination, and subsequently declined slightly but remained elevated until Day 180. At Days 29, 85 and 180, seroresponse rate was 98.3, 97.7 and 96.4% and seroconversion rate was 98.5, 98.4 and 98.2%. There were no differences in seroresponse rate in participants aged 18\u201364\u00a0years or \u226565\u00a0years at Day 29 (98.1 vs 100%), Day 85 (97.4 vs 100%) and Day 180 (96.3 vs 96.5%) nor based on sex, BMI, ethnicity or race. An immune response was shown in a small heterogenous population of baseline seropositive participants, with GMTs showing the same trend as baseline seronegative participants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A single dose of VLA1553 elicited a very strong immune response by Day 29 that remained elevated at Day 180 in both baseline seronegative and seropositive participants in a combined evaluation of two Phase 3 trials. The vaccine was similarly immunogenic in participants aged \u226565\u00a0years and 18\u201364\u00a0years, and there were no differences based on subgroup analyses for sex, BMI, ethnicity or race.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jtm\/taae084","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T22:56:53Z","timestamp":1719961013000},"source":"Crossref","is-referenced-by-count":14,"title":["Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine"],"prefix":"10.1093","volume":"31","author":[{"given":"Vera","family":"Buerger","sequence":"first","affiliation":[{"name":"Valneva Austria GmbH , Campus Vienna Biocenter, 3103 Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Maurer","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Campus Vienna Biocenter, 3103 Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Kosulin","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Campus Vienna Biocenter, 3103 Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"Hochreiter","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Campus Vienna Biocenter, 3103 Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Larcher-Senn","sequence":"additional","affiliation":[{"name":"Assign Data Management and Statistics GmbH , Stadlweg 23, 6020 Innsbruck,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Dubischar","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Campus Vienna Biocenter, 3103 Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Eder-Lingelbach","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Campus Vienna Biocenter, 3103 Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"2024103012060814300_ref1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1056\/NEJMc1505501","article-title":"Chikungunya virus infections","volume":"373","author":"Simon","year":"2015","journal-title":"New Engl J Med"},{"key":"2024103012060814300_ref2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nrrheum.2012.64","article-title":"Arthritogenic alphaviruses\u2014an overview","volume":"8","author":"Suhrbier","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"2024103012060814300_ref3","volume-title":"NIAID Emerging Infectious Diseases\/Pathogens","author":"National Institute of Allergy and Infectious Diseases"},{"key":"2024103012060814300_ref4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1086\/600381","article-title":"Prophylaxis and therapy for chikungunya virus infection","volume":"200","author":"Couderc","year":"2009","journal-title":"J Infect Dis"},{"key":"2024103012060814300_ref5","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cmi.2015.02.024","article-title":"Chikungunya infection: self-reported rheumatic morbidity and impaired quality of life persist 6 years later","volume":"21","author":"Marimoutou","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2024103012060814300_ref6","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1586\/erv.12.84","article-title":"Chikungunya virus and prospects for a vaccine","volume":"11","author":"Weaver","year":"2012","journal-title":"Exp Rev Vacc"},{"key":"2024103012060814300_ref7","volume-title":"Valneva Announces U.S. FDA Approval of World\u2019s First Chikungunya Vaccine, IXCHIQ\u00ae","author":"Valneva"},{"key":"2024103012060814300_ref8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.5811\/westjem.2016.9.30904","article-title":"Dengue, zika and chikungunya: emerging arboviruses in the New World","volume":"17","author":"Patterson","year":"2016","journal-title":"West J Emerg Med"},{"key":"2024103012060814300_ref9","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taad008","article-title":"Chikungunya: risks for travellers","volume":"30","author":"Simon","year":"2023","journal-title":"J Travel Med"},{"key":"2024103012060814300_ref10","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa222","article-title":"Dengue, chikungunya and Zika in GeoSentinel surveillance of international travellers: a literature review from 1995 to 2020","volume":"27","author":"Osman","year":"2020","journal-title":"J Travel Med"},{"key":"2024103012060814300_ref11","article-title":"Causes of fever in returning travelers: a European multicenter prospective cohort study","volume":"29:1\u201312","author":"Camprubi-Ferrer","year":"2022","journal-title":"J Travel Med"},{"key":"2024103012060814300_ref12","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taad062","article-title":"Climate change and vector-borne diseases: a multi-omics approach of temperature-induced changes in the mosquito","volume":"30","author":"Bellone","year":"2023","journal-title":"J Travel Med"},{"key":"2024103012060814300_ref13","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taae005","article-title":"Chikungunya infection in returned travellers: results from the GeoSentinel network, 2005-2020","volume":"31","author":"Bierbrier","year":"2024","journal-title":"J Travel Med"},{"key":"2024103012060814300_ref14","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taae067","article-title":"Trends in imported infections among migrants and travellers to Spain: a decade of analysis through the +Redivi network (2012-2022)","author":"Alkaissy","year":"2024","journal-title":"J Travel Med"},{"key":"2024103012060814300_ref15","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(20)30238-3","article-title":"Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial","volume":"20","author":"Wressnigg","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2024103012060814300_ref16","doi-asserted-by":"crossref","first-page":"e0010069","DOI":"10.1371\/journal.pntd.0010069","article-title":"The global epidemiology of chikungunya from 1999 to 2020: a systematic literature review to inform the development and introduction of vaccines","volume":"16","author":"Bettis","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2024103012060814300_ref17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160173","article-title":"Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera","volume":"7","author":"Roques","year":"2022","journal-title":"JCI Insight"},{"key":"2024103012060814300_ref18","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","article-title":"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicenter, randomized, placebo-controlled phase 3 trial","volume":"401","author":"Schneider","year":"2023","journal-title":"Lancet"},{"key":"2024103012060814300_ref19","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taad156","article-title":"A randomized, double-blinded phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of a live-attenuated chikungunya virus vaccine candidate (VLA1553) in healthy adults","volume":"31","author":"McMahon","year":"2024","journal-title":"J Travel Med"},{"key":"2024103012060814300_ref20","volume-title":"18th Conference of the International Society of Travel Medicine (ISTM)","author":"Buerger"},{"key":"2024103012060814300_ref21","volume-title":"World Vaccine Congress, 1\u20134 April 2024","author":"Eder-Lingelbach"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taae084\/58457805\/taae084.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/31\/7\/taae084\/60220993\/taae084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/31\/7\/taae084\/60220993\/taae084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:48:31Z","timestamp":1730306911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taae084\/7705545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,3]]},"published-print":{"date-parts":[[2024,10,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taae084","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,7,3]]},"article-number":"taae084"}}